Results 151 to 160 of about 68,946 (284)

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia

Онкогематология
Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients.
D. V. Kustova, E. V. Motyko, A. N. Kirienko, T. N. Gert, I. V. Leppyanen, M. P. Bakay, E. V. Efremova, E. V. Morozova, E. G. Lomaia, V. A. Shuvaev, S. V. Sidorkevich, I. S. Martynkevich   +11 more
doaj   +1 more source

Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay [PDF]

, 2002
Hiromitsu Yokota, NH Tsuno, Yoshinori Tanaka, Takafumi Fukui, Kiyoshi Kitamura, Hisamaru Hirai, Kazuoki Osumi, Naoko Itou, Hiroaki Satoh, M Okabe, Ken‐ichi Nakahara   +10 more
openalex   +1 more source

Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR‐ABL‐positive acute lymphoblastic leukemia in Taiwan [PDF]

, 2002
Bor‐Sheng Ko, Jih‐Lu Tang, Fen‐Yu Lee, Ming‐Chi Liu, Woei Tsai, Yee‐Chun Chen, Chiu‐Hwa Wang, Ming‐Chin Sheng, Dong‐Tsam Lin, Kai‐Hsin Lin, Hwei‐Fang Tien   +10 more
openalex   +1 more source

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. [PDF]

Haematologica, 2022
Kayser S, Sartor C, Luskin MR, Webster J, Giglio F, Panitz N, Brunner AM, Fante M, Lutz C, Wolff D, Ho AD, Levis MJ, Schlenk RF, Papayannidis C.   +13 more
europepmc   +1 more source

Resistance of bcr‐abl‐positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 Gene Expression [PDF]

, 2002
Mamta Gupta, Anil Kumar, Sunil Dabadghao
openalex   +1 more source

Is There an Entity of Chemically Induced BCR-ABL–Positive Chronic Myelogenous Leukemia?

The Oncologist, 2008
Abstract Learning Objectives After completing this course, the reader will be able to: Distinguish the exogenous causes of acute and chronic myelogenous leukemia.Discuss the evidence establishing the exogenous causes of secondary leukemia.Describe the relationship of radiation and chemical exposure to
openaire   +3 more sources

Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia

Biomedical Technology
BCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong, Dingrui Nie, Xueting Peng, Kangjie Qiu, Jinyi Liu, Zhangshuai Dai, Xianfeng Zha, Songnan Sui, Weini Li, Weizhang Wang, Cunte Chen, Yangqiu Li, Chengwu Zeng   +12 more
doaj  

Evidence for a positive role of SHIP in the BCR-ABL–mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia [PDF]

, 2003
Xiaoyan Jiang, Matthew Stuible, Yves Chalandon, Andra Li, Wing Yiu Chan, Wolfgang Eisterer, Gerald Krystal, Allen Eaves, Connie J. Eaves   +8 more
openalex   +1 more source

Multiple tests of association with biological annotation metadata

, 2008
We propose a general and formal statistical framework for multiple tests of association between known fixed features of a genome and unknown parameters of the distribution of variable features of this genome in a population of interest.
Mark J. Van Der Laan, Mark J. Van Der Laan, Rine Dudoit, Rine Dudoit Sunduz Keles, Sunduz Keles   +4 more
core   +2 more sources